Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Staiger

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Blood|November 8, 2019
Localized- and advanced-stage follicular lymphomas differ in their gene expression profilesAnnette M Staiger, Eva Hoster, Vindi Jurinovic, et al.
Blood|February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphologyDavid W Scott, Rebecca L King, Annette M Staiger, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Leukemia|December 2, 2015
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locusE Leich, E Hoster, M Wartenberg, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.
Leukemia|November 7, 2025
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving conceptK S Kurz, A Zamo, C Drewes, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Blood|November 8, 2019
Localized- and advanced-stage follicular lymphomas differ in their gene expression profilesAnnette M Staiger, Eva Hoster, Vindi Jurinovic, et al.
Blood|February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphologyDavid W Scott, Rebecca L King, Annette M Staiger, et al.
Blood|July 16, 2016
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapyVindi Jurinovic, Robert Kridel, Annette M Staiger, et al.
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.
Leukemia|September 19, 2019
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHLAnnette M Staiger, Michael Altenbuchinger, Marita Ziepert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2017
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study GroupAnnette M Staiger, Marita Ziepert, Heike Horn, et al.
Leukemia|December 2, 2015
Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locusE Leich, E Hoster, M Wartenberg, et al.
Leukemia|February 18, 2015
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphomaH Horn, M Ziepert, M Wartenberg, et al.
Leukemia & Lymphoma|August 26, 2017
Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYCUlrike Paul, Julia Richter, Christiane Stuhlmann-Laiesz, et al.
Leukemia|November 7, 2025
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving conceptK S Kurz, A Zamo, C Drewes, et al.
Pageof 7